Petros Pharmaceuticals ( (PTPI) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Petros Pharmaceuticals, Inc. has filed a Form 12b-25 announcing a delay in submitting its Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company says the annual report on Form 10-K (Yearly Report) cannot be filed on time because it needs more time to complete and finalize the financial statements required for inclusion.
The company does not cite any auditor change, internal control breakdown, or special committee review as causes, suggesting the delay is driven mainly by timing and workload rather than a specific crisis. Management also indicates that all other required periodic filings over the past 12 months have been submitted, which may reassure investors about the company’s overall reporting discipline.
Petros Pharmaceuticals states that it expects to file its Form 10-K (Yearly Report) within the standard 15-calendar-day extension period allowed under the rules. Investors should therefore anticipate the annual report becoming available within roughly two weeks after the original due date, assuming no further complications arise.
The company does not anticipate any significant change in its results of operations compared with the prior fiscal year, based on what it currently knows. As with any forward-looking statement, this expectation could change once the financials are fully finalized and audited, so investors may still want to review the eventual Form 10-K (Yearly Report) carefully.
Petros notes that it is continuing to work toward full compliance with its SEC reporting obligations and completing the outstanding annual filing. The notification is signed on behalf of the company by President and Chief Commercial Officer Fady Boctor, dated March 31, 2026, formally confirming management’s responsibility for the delayed filing notice.
More about Petros Pharmaceuticals
Technical Sentiment Signal: Sell
Current Market Cap: $258.5K
See more insights into PTPI stock on TipRanks’ Stock Analysis page.